Effect of a high dose atorvastatin as adjuvant therapy to mesalamine in attenuating inflammation and symptoms in patients with ulcerative colitis: a randomized controlled pilot study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Atorvastatin shows promise as an add-on treatment for ulcerative colitis (UC), significantly reducing inflammatory markers and improving patient outcomes. This study explored its effects on key inflammatory pathways in UC patients.
Area Of Science
- Gastroenterology
- Pharmacology
- Immunology
Background
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease affecting the colon.
- Preclinical studies suggest atorvastatin may have beneficial effects in managing colitis.
- Key inflammatory pathways, including sphingosine 1 phosphate (S1P)/tumor necrosis factor-alpha (TNF-α)/interleukin-6 (IL-6), are implicated in UC pathogenesis.
Purpose Of The Study
- To investigate the therapeutic role of atorvastatin in modulating the S1P/TNF-α/IL-6 pathway in patients with ulcerative colitis.
- To assess the efficacy of atorvastatin as an adjunctive therapy for mild to moderate UC.
Main Methods
- A 6-month pilot study involving patients with mild to moderate UC.
- Two groups: placebo plus mesalamine vs. atorvastatin (80 mg daily) plus mesalamine.
- Evaluated colitis severity (partial Mayo score index), inflammatory biomarkers (IL-6, S1P, TNF-α, NO, ESR, CRP, fecal calprotectin), and quality of life (SF-36).
Main Results
- The atorvastatin group showed significant reductions in IL-6, S1P, TNF-α, NO, CRP, ESR, and fecal calprotectin compared to placebo (p < 0.015 for all).
- Atorvastatin treatment led to a significant decrease in partial Mayo score index (p=0.013) and improved SF-36 scores (p=0.006).
- Higher response (91.3% vs. 83.3%) and remission (60.8% vs. 45.8%) rates were observed in the atorvastatin group.
Conclusions
- Atorvastatin demonstrated a significant positive impact on inflammatory markers and clinical outcomes in UC patients.
- The findings suggest that atorvastatin can be considered as a potential adjunctive therapy for ulcerative colitis.
- Further research is warranted to confirm these findings in larger patient cohorts.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...